AbbVie Inc. (ABBV) To Go Ex-Dividend on July 15th

AbbVie Inc. (NYSE:ABBV) declared a quarterly dividend on Thursday, June 18th. Shareholders of record on Wednesday, July 15th will be paid a dividend of 1.73 per share on Friday, August 14th. This represents a c) dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th.

AbbVie has increased its dividend by an average of 0.1%annually over the last three years and has raised its dividend annually for the last 53 consecutive years. AbbVie has a payout ratio of 49.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect AbbVie to earn $16.04 per share next year, which means the company should continue to be able to cover its $6.92 annual dividend with an expected future payout ratio of 43.1%.

AbbVie Stock Down 0.0%

Shares of NYSE ABBV opened at $248.00 on Monday. The stock’s 50 day moving average price is $225.42 and its two-hundred day moving average price is $221.20. AbbVie has a 52-week low of $184.63 and a 52-week high of $261.64. The stock has a market capitalization of $438.17 billion, a P/E ratio of 122.17, a PEG ratio of 0.81 and a beta of 0.30.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the firm posted $2.46 EPS. The company’s revenue for the quarter was up 12.4% on a year-over-year basis. On average, analysts anticipate that AbbVie will post 14.3 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Bank of America raised AbbVie’s price target to $276 from $234 and reiterated a buy rating, signaling confidence in additional upside for the shares. Bank of America raises AbbVie price target
• Positive Sentiment: RBC Capital also increased its price target to $280 from $260 and kept an outperform rating, adding to the wave of analyst support. RBC raises AbbVie price target
• Positive Sentiment: JPMorgan likewise lifted its target to $280 from $260 and maintained an overweight rating, reinforcing a favorable near-term outlook for AbbVie. JPMorgan raises AbbVie price target
• Neutral Sentiment: Recent coverage comparing Johnson & Johnson and AbbVie highlighted how both pharma giants’ latest quarterly results are shaping income-investor preferences, but it did not point to a clear new catalyst for AbbVie. Johnson & Johnson vs AbbVie article
• Neutral Sentiment: AbbVie also appeared in an industry piece on the expanding cystic fibrosis market, which may be supportive of long-term therapeutic demand but is not an immediate stock-moving event. Cystic fibrosis market article
• Negative Sentiment: Despite the analyst upgrades, AbbVie was recently reported as having moved lower in trading, suggesting the stock is still contending with profit-taking or broader market pressure. AbbVie stock drops despite market gains
• Neutral Sentiment: West Pharmaceutical completed the SmartDose sale to AbbVie, a routine transaction that may support AbbVie’s drug-delivery capabilities but is unlikely to move the stock on its own. West Pharmaceutical SmartDose sale to AbbVie

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.